Monaco Asset Management SAM Has $1.49 Million Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Key Points

• Monaco Asset Management SAM reduced its stake in Vanda Pharmaceuticals by 17.1% during the first quarter, now holding 325,000 shares worth approximately $1.49 million.
• Vanda Pharmaceuticals reported better-than-expected quarterly earnings with an EPS of ($0.50), surpassing estimates of ($0.55), along with a revenue of $50.04 million.
• Equities analysts have set varying price targets for VNDA, with Cantor Fitzgerald maintaining an "overweight" rating and a target of $13.00, while HC Wainwright set a $20.00 price target.

Monaco Asset Management SAM trimmed its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 17.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 325,000 shares of the biopharmaceutical company's stock after selling 67,262 shares during the quarter. Monaco Asset Management SAM owned about 0.55% of Vanda Pharmaceuticals worth $1,492,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Norges Bank bought a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth approximately $551,000. Dimensional Fund Advisors LP increased its stake in shares of Vanda Pharmaceuticals by 10.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company's stock valued at $11,920,000 after acquiring an additional 227,428 shares during the last quarter. Two Sigma Investments LP increased its stake in shares of Vanda Pharmaceuticals by 94.7% in the 4th quarter. Two Sigma Investments LP now owns 199,460 shares of the biopharmaceutical company's stock valued at $955,000 after acquiring an additional 97,017 shares during the last quarter. GSA Capital Partners LLP increased its stake in shares of Vanda Pharmaceuticals by 88.0% in the 1st quarter. GSA Capital Partners LLP now owns 260,215 shares of the biopharmaceutical company's stock valued at $1,194,000 after acquiring an additional 121,797 shares during the last quarter. Finally, Empire Financial Management Company LLC bought a new stake in shares of Vanda Pharmaceuticals in the 4th quarter valued at about $307,000. 88.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

VNDA has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th. Wall Street Zen cut Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Saturday. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th.

Vanda Pharmaceuticals Stock Down 1.6%

Shares of VNDA traded down $0.07 on Friday, hitting $4.19. The company's stock had a trading volume of 766,997 shares, compared to its average volume of 520,925. The firm's fifty day moving average price is $4.64 and its 200-day moving average price is $4.54. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.81 and a fifty-two week high of $5.56. The firm has a market capitalization of $246.93 million, a price-to-earnings ratio of -3.71 and a beta of 0.68.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.12). The business had revenue of $52.59 million during the quarter, compared to analyst estimates of $54.77 million. Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative return on equity of 12.89%. As a group, equities analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Insider Activity at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 7,000 shares of the firm's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $4.59, for a total transaction of $32,130.00. Following the completion of the transaction, the director directly owned 97,082 shares of the company's stock, valued at $445,606.38. This trade represents a 6.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Mihael Hristos Polymeropoulos purchased 20,000 shares of the firm's stock in a transaction dated Friday, May 16th. The shares were acquired at an average cost of $4.22 per share, with a total value of $84,400.00. Following the completion of the purchase, the chief executive officer directly owned 2,315,731 shares in the company, valued at approximately $9,772,384.82. This represents a 0.87% increase in their ownership of the stock. The disclosure for this purchase can be found here. 10.00% of the stock is owned by company insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.